The following refers to our Seralite® – FLC product.
Clinicians are able to better understand disease status and can make informed decisions quickly and efficiently.
Seralite®– FLC helps address the many challenges associated with the diagnosis and management of Multiple Myeloma and other B Cell Dyscrasias.
Monoclonal FLC are important disease biomarkers in patients with myeloma and related disorders.
The features of the Seralite® – FLC device provide numerous informative and empowering benefits to clinicians and laboratories. By obtaining results rapidly, clinicians are able to better understand disease status.
B-cell dyscrasias are disorders of the plasma cells, characterised by the abnormal proliferation of a monoclonal population of plasma cells.